Month: November 2021

Recently I am researching about DRUG-REACTIONS; MEDICATION USE; OLDER-PEOPLE; CARE; COMORBIDITIES, Saw an article supported by the Alzheimer’s Society [338 (AS-JF-16b007)]. Published in OXFORD UNIV PRESS in OXFORD ,Authors: Delgado, J; Jones, L; Bradley, MC; Allan, LM; Ballard, C; Clare, L; Fortinsky, RH; Hughes, CM; Melzer, D. The CAS is 83-10-3. Through research, I have a further understanding and discovery of 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid. Recommanded Product: 83-10-3

Importance: treatment of dementia in individuals with comorbidities is complex, leading to potentially inappropriate prescribing (PIP). The impact of PIP in this population is unknown. Objective: to estimate the rate of PIP and its effect on adverse health outcomes (AHO). Design: retrospective cohort. Setting: primary care electronic health records linked to hospital discharge data from England. Subjects: 11,175 individuals with dementia aged over 65 years in 2016 and 43,463 age- and sex-matched controls. Methods: Screening Tool of Older Persons’ Prescriptions V2 defined PIP. Logistic regression tested associations with comorbidities at baseline, and survival analyses risk of incident AHO, adjusted for age, gender, deprivation and 14 comorbidities. Results: the dementia group had increased risk of PIP (73% prevalence; odds ratio [OR]: 1.92; confidence interval [CI]: 83-103%; P < 0.01) after adjusting for comorbidities. Most frequent PIP criteria were related to anti-cholinergic drugs and therapeutic duplication. Risk of PIP was higher in patients also diagnosed with coronary-heart disease (odds OR: 2.17; CI: 1.91-2.46; P < 0.01), severe mental illness (OR: 2.09; CI: 1.62-2.70; P < 0.01); and depression (OR: 1.81; CI: 1.62-2.01; P < 0.01). During follow-up (1 year), PIP was associated with increased all-cause mortality (hazard ratio: 1.14; CI: 1.021.26; P < 0.02), skin ulcer and pressure sores (hazard ratio: 1.66; CI: 1.12-2.46; P< 0.01), falls (hazard ratio: 1.37; CI: 1.15-1.63; P < 0.01), anaemia (hazard ratio: 1.61; CI: 1.10-2.38; P < 0.02) and osteoporosis (hazard ratio: 1.62; CI: 1.022.57; P < 0.04). Conclusion: patients with dementia frequently receive PIPs, and those who do are more likely to experience AHO. These results highlight the need to optimise medication in dementia patients, especially those with comorbidities. About 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid, If you have any questions, you can contact Delgado, J; Jones, L; Bradley, MC; Allan, LM; Ballard, C; Clare, L; Fortinsky, RH; Hughes, CM; Melzer, D or concate me.. Recommanded Product: 83-10-3

Reference:
Patent; Shanghai Pharmaceutical Industry Institute; China Pharmaceutical Industry Zongyuan; Li Jianqi; Huang Daowei; Wang Wenya; Zhang Zhiguo; Jiang Ling; (45 pag.)CN107286140; (2017); A;,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

I found the field of Chemistry very interesting. Saw the article Catalytic Asymmetric Addition of Diorganozinc Reagents to Pyrazole-4,5-Diones and Indoline-2,3-Diones published in 2021. Recommanded Product: 86-92-0, Reprint Addresses Xiao, YC; Chen, FE (corresponding author), Sichuan Univ, Sichuan Res Ctr Drug Precis Ind Technol, West China Sch Pharm, Chengdu 610041, Peoples R China.; Chen, FE (corresponding author), Fudan Univ, Engn Ctr Catalysis & Synth Chiral Mol, Dept Chem, Shanghai 200433, Peoples R China.; Chen, FE (corresponding author), Shanghai Engn Ctr Ind Asymmetr Catalysis Chiral D, Shanghai 200433, Peoples R China.. The CAS is 86-92-0. Through research, I have a further understanding and discovery of 3-Methyl-1-p-tolyl-5-pyrazolone

The catalytic enantioselective diorganozinc additions to cyclic diketones including pyrazolin-4,5-diones and isatins have been developed. In the presence of morpholine-containing chiral amino alcohol ligand, the corresponding chiral cyclic tertiary alcohols were produced in good to excellent yields (up to 97 %) and enantioselectivities (up to 95 % ee). The notable feature of this protocol includes its mild reaction conditions, Lewis acid additives free and broad functional group tolerance.

Recommanded Product: 86-92-0. About 3-Methyl-1-p-tolyl-5-pyrazolone, If you have any questions, you can contact Wang, RH; Li, YL; He, HJ; Xiao, YC; Chen, FE or concate me.

Reference:
Article; Zhang, Yong; Nie, Long-Jun; Luo, Liang; Mao, Jia-Xin; Liu, Jin-Xiang; Xu, Guo-Hai; Chen, Deliang; Luo, Hai-Qing; Tetrahedron; vol. 76; 7; (2020);,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Authors Novakova-Jiresova, A; Kopeckova, K; Boublikova, L; Chloupkov, R; Melichar, B; Petruzelka, L; Finek, J; Fiala, O; Grell, P; Batko, S; Linke, Z; Kiss, I; Prausov, J; Buchler, T in DOVE MEDICAL PRESS LTD published article about CLINICAL-PRACTICE; SURVIVAL; MULTICENTER; ANTITUMOR; SAFETY; SITE; SEX in [Novakova-Jiresova, Alena; Boublikova, Ludmila; Buchler, Tomas] Charles Univ Prague, Fac Med 1, Dept Oncol, Videnska 800, Prague 14059, Czech Republic; [Novakova-Jiresova, Alena; Boublikova, Ludmila; Buchler, Tomas] Charles Univ Prague, Thomayer Hosp, Videnska 800, Prague 14059, Czech Republic; [Kopeckova, Katerina; Batko, Stanislav; Linke, Zdenek; Prausov, Jana] Charles Univ Prague, Univ Hosp Motol, Dept Oncol, Prague, Czech Republic; [Chloupkov, Renata] Masaryk Univ, Fac Med, Inst Biostat & Anal, Brno, Czech Republic; [Melichar, Bohuslav] Palacky Univ Med, Dept Oncol, Olomouc, Czech Republic; [Melichar, Bohuslav] Teaching Hosp, Olomouc, Czech Republic; [Petruzelka, Lubos] Charles Univ Prague, Gen Fac Hosp, Dept Oncol, Prague, Czech Republic; [Finek, Jindrich; Fiala, Ondrej] Charles Univ Prague, Med Sch, Dept Oncol & Radiotherapy, Plzen, Czech Republic; [Finek, Jindrich; Fiala, Ondrej] Charles Univ Prague, Univ Hosp Pilsen, Plzen, Czech Republic; [Fiala, Ondrej] Charles Univ Prague, Fac Med Pilsen, Biomed Ctr, Plzen, Czech Republic; [Grell, Peter; Kiss, Igor] Masaryk Mem Canc Inst, Dept Comprehens Canc Care, Brno, Czech Republic in 2020, Cited 30. Safety of 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid. The Name is 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid. Through research, I have a further understanding and discovery of 83-10-3

Purpose: Regorafenib is an oral multikinase inhibitor approved for the therapy of previously treated metastatic colorectal carcinoma (mCRC). The aim of the present study was to analyze the outcomes of treatment with regorafenib in real-world clinical practice based on data from a national registry. Methods: The CORECT registry, the Czech non-interventional database of patients with mCRC treated with targeted agents, searched for patients with metastatic CRC treated with regorafenib. In total, 555 evaluable patients were identified. Results: The median age at diagnosis was 61.7 years. All patients had disease progression on or after previous systemic treatment. Most patients were treated with an initial dose of 160 mg daily (n = 463; 83.6%). The median duration of treatment was 2.7 months (range 0.023.4 months). By the data cut-off date, 472 patients (85%) had completed treatment with regorafenib and were evaluable for treatment response evaluation. Partial response was reported in 13 patients (2.8%) and disease stabilization in 130 patients (27.5%). Median progression-free survival (PFS) and overall survival (OS) were 3.5 months (95% confidence interval [CI] 3.2-3.7 months) and 9.3 months (95% CI 8.3-10.3 months), respectively. The 6-month OS rate was 67.7% (95% CI 63.4-72.1%). Multivariable analysis showed that female gender, longer interval from diagnosis of metastatic disease, MO stage at diagnosis, and Eastern Cooperative Oncology Group performance status (ECOG PS) 0 were associated with longer PFS, while higher body-mass index (BMI), longer interval from diagnosis of metastatic disease, and ECOG PS of 0 were associated with longer OS. Conclusion: OS of patients treated with regorafenib in the real-world clinical practice in this cohort exceeded that reported in randomized trials. Regorafenib is a safe and active treatment option for a subgroup of patients with mCRC who are progressing after other systemic therapies and maintain good performance status.

Safety of 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid. Welcome to talk about 83-10-3, If you have any questions, you can contact Novakova-Jiresova, A; Kopeckova, K; Boublikova, L; Chloupkov, R; Melichar, B; Petruzelka, L; Finek, J; Fiala, O; Grell, P; Batko, S; Linke, Z; Kiss, I; Prausov, J; Buchler, T or send Email.

Reference:
Patent; Shanghai Pharmaceutical Industry Institute; China Pharmaceutical Industry Zongyuan; Li Jianqi; Huang Daowei; Wang Wenya; Zhang Zhiguo; Jiang Ling; (45 pag.)CN107286140; (2017); A;,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

An article Potentially inappropriate prescribing in dementia, multi-morbidity and incidence of adverse health outcomes WOS:000649434300024 published article about DRUG-REACTIONS; MEDICATION USE; OLDER-PEOPLE; CARE; COMORBIDITIES in [Delgado, Joao; Jones, Lindsay; Ballard, Clive; Melzer, David] Univ Exeter, Coll Med & Hlth, Epidemiol & Publ Hlth, Exeter EX1 2LU, Devon, England; [Bradley, Marie C.] US FDA, Off Surveillance & Epidemiol, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA; [Allan, Louise M.; Clare, Linda] Univ Exeter, Coll Med & Hlth, Ctr Res Ageing & Cognit Hlth, Exeter EX1 2LU, Devon, England; [Fortinsky, Richard H.] Univ Connecticut, Sch Med, Ctr Aging, Mansfield, CT 06030 USA; [Hughes, Carmel M.] Queens Univ Belfast, Med Biol Ctr, Sch Pharm, Belfast BT9 7BL, Antrim, North Ireland in 2021, Cited 30. Recommanded Product: 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid. The Name is 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid. Through research, I have a further understanding and discovery of 83-10-3

Importance: treatment of dementia in individuals with comorbidities is complex, leading to potentially inappropriate prescribing (PIP). The impact of PIP in this population is unknown. Objective: to estimate the rate of PIP and its effect on adverse health outcomes (AHO). Design: retrospective cohort. Setting: primary care electronic health records linked to hospital discharge data from England. Subjects: 11,175 individuals with dementia aged over 65 years in 2016 and 43,463 age- and sex-matched controls. Methods: Screening Tool of Older Persons’ Prescriptions V2 defined PIP. Logistic regression tested associations with comorbidities at baseline, and survival analyses risk of incident AHO, adjusted for age, gender, deprivation and 14 comorbidities. Results: the dementia group had increased risk of PIP (73% prevalence; odds ratio [OR]: 1.92; confidence interval [CI]: 83-103%; P < 0.01) after adjusting for comorbidities. Most frequent PIP criteria were related to anti-cholinergic drugs and therapeutic duplication. Risk of PIP was higher in patients also diagnosed with coronary-heart disease (odds OR: 2.17; CI: 1.91-2.46; P < 0.01), severe mental illness (OR: 2.09; CI: 1.62-2.70; P < 0.01); and depression (OR: 1.81; CI: 1.62-2.01; P < 0.01). During follow-up (1 year), PIP was associated with increased all-cause mortality (hazard ratio: 1.14; CI: 1.021.26; P < 0.02), skin ulcer and pressure sores (hazard ratio: 1.66; CI: 1.12-2.46; P< 0.01), falls (hazard ratio: 1.37; CI: 1.15-1.63; P < 0.01), anaemia (hazard ratio: 1.61; CI: 1.10-2.38; P < 0.02) and osteoporosis (hazard ratio: 1.62; CI: 1.022.57; P < 0.04). Conclusion: patients with dementia frequently receive PIPs, and those who do are more likely to experience AHO. These results highlight the need to optimise medication in dementia patients, especially those with comorbidities. Recommanded Product: 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid. Bye, fridends, I hope you can learn more about C12H12N2O3, If you have any questions, you can browse other blog as well. See you lster.

Reference:
Patent; Shanghai Pharmaceutical Industry Institute; China Pharmaceutical Industry Zongyuan; Li Jianqi; Huang Daowei; Wang Wenya; Zhang Zhiguo; Jiang Ling; (45 pag.)CN107286140; (2017); A;,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

I found the field of Chemistry very interesting. Saw the article Structural diversity of ethylzinc derivatives of 3,5-substituted pyrazoles published in 2020.0. HPLC of Formula: C5H8N2, Reprint Addresses Lewinski, J (corresponding author), Warsaw Univ Technol, Dept Chem, Noakowskiego 3, PL-00664 Warsaw, Poland.; Lewinski, J (corresponding author), Polish Acad Sci, Inst Phys Chem, Kasprzaka 44-52, PL-01224 Warsaw, Poland.. The CAS is 67-51-6. Through research, I have a further understanding and discovery of 3,5-Dimethyl-1H-pyrazole

Equimolar reactions of Et2Zn with 3,5-dimethylpyrazole (H-pz(Me2)), 3,5-di-iso-propylpyrazole (H-pz(iPr2)), 3,5-di-tert-butylpyrazole (H-pz(tBu2)) and indazole (H-ind) were investigated in toluene or tetrahydrofuran (as a coordinating solvent). A series of diverse ethylzinc pyrazolates and indazolates were identified using advanced NMR spectroscopy and the single crystal X-ray diffraction techniques. The NMR experiments indicate that dimeric moieties of the general formula [EtZn(pz)](2) or [Et2Zn2(pz)(2)(THF)] are favoured in solution. Nevertheless, these types of complexes are kinetically labile and tend to undergo ligand scrambling reactions according to the Schlenk equilibrium. For example, the alkyl substituents in the pz(Me2) and pz(iPr2) ligands do not appear to be a strong determinant of the dimeric moieties and the composition of the isolated complexes by crystallisation from the parent reaction mixture varies between spiro-type tri- and tetranuclear aggregates, [Et2Zn3(pz)(4)(THF)(x)] (x = 0 or 2) and [Et2Zn4(pz)(6)(THF)(2)], respectively. The nonstoichiometric formula of these organozinc derivatives is likely related to both the Schlenk-type equilibria and solubility of the respective moieties. In turn, the high steric demands of the 3,5-di-tert-butylpyrazolate ligand promote the dimeric form in solution and the solid state. Interestingly, the ethylzinc indazolate complex also does not undergo a redistribution reaction and yields a dimer.

HPLC of Formula: C5H8N2. Bye, fridends, I hope you can learn more about C5H8N2, If you have any questions, you can browse other blog as well. See you lster.

Reference:
Pyrazole – Wikipedia,
,Pyrazoles – an overview | ScienceDirect Topics

Recently I am researching about DNA-BINDING; PLASMODIUM-FALCIPARUM; COPPER(II) COMPLEXES; CU(II) COMPLEXES; DERIVATIVES; ANTICANCER; BINARY, Saw an article supported by the . Published in PERGAMON-ELSEVIER SCIENCE LTD in OXFORD ,Authors: Shaikh, I; Jadeja, RN; Patel, R. The CAS is 86-92-0. Through research, I have a further understanding and discovery of 3-Methyl-1-p-tolyl-5-pyrazolone. Recommanded Product: 86-92-0

Three novel mixed ligand Zn(II) complexes {complex 1 = [Zn(L1)(2)(bpy)], complex 2 = [Zn(L2)(2)(bPY)], complex 3 = [Zn(L2)(2)(phen)], where bpy = 2,2′-bipyridine and phen = 1,10-phenanthroline} of 4-(4-chlorobenzoyl)-2-(3-chlorophenyl)-5-methyl-2,4-dihydro-3H-pyrazol-3-one (HL1) and 4-(4-chlorobenzoyl)-5-methyl-2-(p-tolyl)-2,4-dihydro-3H-pyrazol-3-one (HL2) were synthesized and characterized by H-1 and C-13 NMR, FTIR, TG-DTA, UV-Vis, elemental analysis, molar conductance and single crystal X-ray structure determination. Based on analytical and spectroscopic techniques, all the three Zn(II) complexes were found to have a distorted octahedral geometry. The ligands and the complexes were screened for antimalarial activity against plasmodium falciparum. The zinc(II) complexes showed greater antimalarial activity than their parent ligands. (C) 2020 Elsevier Ltd. All rights reserved.

Bye, fridends, I hope you can learn more about C11H12N2O, If you have any questions, you can browse other blog as well. See you lster.. Recommanded Product: 86-92-0

Reference:
Article; Zhang, Yong; Nie, Long-Jun; Luo, Liang; Mao, Jia-Xin; Liu, Jin-Xiang; Xu, Guo-Hai; Chen, Deliang; Luo, Hai-Qing; Tetrahedron; vol. 76; 7; (2020);,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

SDS of cas: 86-92-0. Recently I am researching about PHOTOPHYSICAL PROPERTIES; ACTIVATION; FUNCTIONALIZATION; MECHANISM, Saw an article supported by the SERB-New DelhiDepartment of Science & Technology (India)Science Engineering Research Board (SERB), India [CRG/2019/001898]; DSTDepartment of Science & Technology (India). Published in ROYAL SOC CHEMISTRY in CAMBRIDGE ,Authors: Changmai, S; Sultana, S; Sarma, B; Gogoi, S. The CAS is 86-92-0. Through research, I have a further understanding and discovery of 3-Methyl-1-p-tolyl-5-pyrazolone

The Pd(ii)-catalyzed activation of Csp(2)-H bond and double alkyne annulation which proceeds via allylic isomerization is reported for the first time. This reaction of antipyrines with alkynes provides an efficient synthetic route for the biologically important spiro-cyclopentadiene pyrazolones. In the presence of Lawesson’s reagent, this Pd(ii)-catalyzed annulation reaction affords another spiro-cyclopentadiene pyrazolone which displays very good fluorescence properties.

SDS of cas: 86-92-0. Bye, fridends, I hope you can learn more about C11H12N2O, If you have any questions, you can browse other blog as well. See you lster.

Reference:
Article; Zhang, Yong; Nie, Long-Jun; Luo, Liang; Mao, Jia-Xin; Liu, Jin-Xiang; Xu, Guo-Hai; Chen, Deliang; Luo, Hai-Qing; Tetrahedron; vol. 76; 7; (2020);,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Recently I am researching about MAGNESIUM-DL-ASPARTATE; P-TOLUIC ACID; MIXING PROPERTIES; ACTIVITY-COEFFICIENT; NRTL-SAC; 313.15 K; PREDICTION; INGREDIENTS; PARAMETERS, Saw an article supported by the Payame Noor University. Published in ELSEVIER in AMSTERDAM ,Authors: Akbari, F; Didehban, K; Farhang, M. The CAS is 86-92-0. Through research, I have a further understanding and discovery of 3-Methyl-1-p-tolyl-5-pyrazolone. Recommanded Product: 3-Methyl-1-p-tolyl-5-pyrazolone

A new semi-theoretical equation is suggested for correlation of solid-liquid solubility data with temperature. The (solid + liquid) equilibrium for Terephthaldialdehyde, 4-Nitro-o-phennylenediamine, 2,4-dihydro- 5-methyl-2(4-methylphenyl)-3H-pyrazol-3-one (also named 1-(p-toly1)-3-methyl-5pyrazolone (PTMP)), 2-Amino-5-methylthiazole and 5-chloro-1-methyl-4-nitroimidazole in 18 solvents is correlated with semi-empirical models at temperatures T = 273.15 – 318.15 K under a pressure of 101.2 kPa. Moreover, a modified Apelblat model, lambda h model, Wilson model, NRTL model, new flexible equation as Akbari, Dideban and Farhang model (ADF) and for first time the modified Scatchard-Hildebrand equation were utilized to calculate the experiment values. The performance of both ADF and modified Scatchard-Hildebrand equation have been checked by calculating the solubility data with the AARD% of 1.3808% (for 775 data points) and 0.65% (for 100 data points), respectively. The Wilson model is applied to estimate the mixing Gibbs energy, mixing enthalpy, mixing entropy, activity coefficient (ln gamma(infinity)(1)) and reduced excess enthalpy (H-I(E,infinity)) at infinitesimal concentration were calculated.

Recommanded Product: 3-Methyl-1-p-tolyl-5-pyrazolone. Welcome to talk about 86-92-0, If you have any questions, you can contact Akbari, F; Didehban, K; Farhang, M or send Email.

Reference:
Article; Zhang, Yong; Nie, Long-Jun; Luo, Liang; Mao, Jia-Xin; Liu, Jin-Xiang; Xu, Guo-Hai; Chen, Deliang; Luo, Hai-Qing; Tetrahedron; vol. 76; 7; (2020);,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

An article Solubility of solid intermediate of pharmaceutical compounds in pure organic solvents using semi-empirical models WOS:000507620300035 published article about MAGNESIUM-DL-ASPARTATE; P-TOLUIC ACID; MIXING PROPERTIES; ACTIVITY-COEFFICIENT; NRTL-SAC; 313.15 K; PREDICTION; INGREDIENTS; PARAMETERS in [Akbari, Falamarz] Eram Inst Higher Educ, Dept Chem, POB 71957-46733, Shiraz, Iran; [Didehban, Khadijeh; Farhang, Mona] Payame Noor Univ, Dept Chem, POB 19395-3697, Tehran, Iran in 2020, Cited 35. The Name is 3-Methyl-1-p-tolyl-5-pyrazolone. Through research, I have a further understanding and discovery of 86-92-0. Computed Properties of C11H12N2O

A new semi-theoretical equation is suggested for correlation of solid-liquid solubility data with temperature. The (solid + liquid) equilibrium for Terephthaldialdehyde, 4-Nitro-o-phennylenediamine, 2,4-dihydro- 5-methyl-2(4-methylphenyl)-3H-pyrazol-3-one (also named 1-(p-toly1)-3-methyl-5pyrazolone (PTMP)), 2-Amino-5-methylthiazole and 5-chloro-1-methyl-4-nitroimidazole in 18 solvents is correlated with semi-empirical models at temperatures T = 273.15 – 318.15 K under a pressure of 101.2 kPa. Moreover, a modified Apelblat model, lambda h model, Wilson model, NRTL model, new flexible equation as Akbari, Dideban and Farhang model (ADF) and for first time the modified Scatchard-Hildebrand equation were utilized to calculate the experiment values. The performance of both ADF and modified Scatchard-Hildebrand equation have been checked by calculating the solubility data with the AARD% of 1.3808% (for 775 data points) and 0.65% (for 100 data points), respectively. The Wilson model is applied to estimate the mixing Gibbs energy, mixing enthalpy, mixing entropy, activity coefficient (ln gamma(infinity)(1)) and reduced excess enthalpy (H-I(E,infinity)) at infinitesimal concentration were calculated.

About 3-Methyl-1-p-tolyl-5-pyrazolone, If you have any questions, you can contact Akbari, F; Didehban, K; Farhang, M or concate me.. Computed Properties of C11H12N2O

Reference:
Article; Zhang, Yong; Nie, Long-Jun; Luo, Liang; Mao, Jia-Xin; Liu, Jin-Xiang; Xu, Guo-Hai; Chen, Deliang; Luo, Hai-Qing; Tetrahedron; vol. 76; 7; (2020);,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Name: 3-Methyl-1-p-tolyl-5-pyrazolone. Wang, RH; Li, YL; He, HJ; Xiao, YC; Chen, FE in [Wang, Rong-Hui; Li, Ya-Ling; He, Hong-Jiao; Xiao, You-Cai; Chen, Fen-Er] Sichuan Univ, Sichuan Res Ctr Drug Precis Ind Technol, West China Sch Pharm, Chengdu 610041, Peoples R China; [Chen, Fen-Er] Fudan Univ, Engn Ctr Catalysis & Synth Chiral Mol, Dept Chem, Shanghai 200433, Peoples R China; [Chen, Fen-Er] Shanghai Engn Ctr Ind Asymmetr Catalysis Chiral D, Shanghai 200433, Peoples R China published Catalytic Asymmetric Addition of Diorganozinc Reagents to Pyrazole-4,5-Diones and Indoline-2,3-Diones in 2021, Cited 67. The Name is 3-Methyl-1-p-tolyl-5-pyrazolone. Through research, I have a further understanding and discovery of 86-92-0.

The catalytic enantioselective diorganozinc additions to cyclic diketones including pyrazolin-4,5-diones and isatins have been developed. In the presence of morpholine-containing chiral amino alcohol ligand, the corresponding chiral cyclic tertiary alcohols were produced in good to excellent yields (up to 97 %) and enantioselectivities (up to 95 % ee). The notable feature of this protocol includes its mild reaction conditions, Lewis acid additives free and broad functional group tolerance.

Welcome to talk about 86-92-0, If you have any questions, you can contact Wang, RH; Li, YL; He, HJ; Xiao, YC; Chen, FE or send Email.. Name: 3-Methyl-1-p-tolyl-5-pyrazolone

Reference:
Article; Zhang, Yong; Nie, Long-Jun; Luo, Liang; Mao, Jia-Xin; Liu, Jin-Xiang; Xu, Guo-Hai; Chen, Deliang; Luo, Hai-Qing; Tetrahedron; vol. 76; 7; (2020);,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics